Takamori S, Takada K, Shimokawa M, et al. - Researchers investigated the clinical utility of inflammatory indices, including Glasgow prognostic score (GPS), modified Glasgow prognostic score (mGPS), and C-reactive protein/albumin ratio (CAR) in non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). This study involved 304 patients who were managed with ICI monotherapy for advanced or recurrent NSCLC. Data on patient demographics, GPS, mGPS, and CAR at diagnosis were obtained. The most significant correlation with the degree of disease control rate among the three indices was displayed by GPS. Superior time-dependent area under curve values were yielded by GPS, compared to mGPS and CAR, for overall survival (OS) prediction. A significant correlation of GPS with performance status and clinical stage was identified. In multivariable analysis, GPS was identified as an independent predictor of PFS and OS. Findings revealed, for the first time, that GPS is not only a simple but also a useful prognostic factor in NSCLC patients managed with ICIs, and deserves to be validated prospectively.